595 related articles for article (PubMed ID: 32669658)
1. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L; Ofengeim D; Yuan J
Nat Rev Drug Discov; 2020 Aug; 19(8):553-571. PubMed ID: 32669658
[TBL] [Abstract][Full Text] [Related]
2. Targeting RIPK1 for the treatment of human diseases.
Degterev A; Ofengeim D; Yuan J
Proc Natl Acad Sci U S A; 2019 May; 116(20):9714-9722. PubMed ID: 31048504
[TBL] [Abstract][Full Text] [Related]
3. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
4. Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.
Lule S; Wu L; McAllister LM; Edmiston WJ; Chung JY; Levy E; Zheng Y; Gough PJ; Bertin J; Degterev A; Lo EH; Whalen MJ
Stroke; 2017 Sep; 48(9):2549-2556. PubMed ID: 28765287
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
6. RIPK1: A rising star in inflammatory and neoplastic skin diseases.
Jin L; Liu P; Yin M; Zhang M; Kuang Y; Zhu W
J Dermatol Sci; 2020 Sep; 99(3):146-151. PubMed ID: 32600738
[TBL] [Abstract][Full Text] [Related]
7. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death.
Dondelinger Y; Delanghe T; Rojas-Rivera D; Priem D; Delvaeye T; Bruggeman I; Van Herreweghe F; Vandenabeele P; Bertrand MJM
Nat Cell Biol; 2017 Oct; 19(10):1237-1247. PubMed ID: 28920952
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
9. Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.
Hamilton GL; Chen H; Deshmukh G; Eigenbrot C; Fong R; Johnson A; Kohli PB; Lupardus PJ; Liederer BM; Ramaswamy S; Wang H; Wang J; Xu Z; Zhu Y; Vucic D; Patel S
Bioorg Med Chem Lett; 2019 Jun; 29(12):1497-1501. PubMed ID: 31000154
[TBL] [Abstract][Full Text] [Related]
10. Necroptosis in development and diseases.
Shan B; Pan H; Najafov A; Yuan J
Genes Dev; 2018 Mar; 32(5-6):327-340. PubMed ID: 29593066
[TBL] [Abstract][Full Text] [Related]
11. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development.
Bai Y; Qiao Y; Li M; Yang W; Chen H; Wu Y; Zhang H
Eur J Med Chem; 2024 Feb; 265():116123. PubMed ID: 38199165
[TBL] [Abstract][Full Text] [Related]
12. Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present).
Xu L; Zhang W; Zhuang C
Expert Opin Ther Pat; 2023 Feb; 33(2):101-124. PubMed ID: 36960668
[TBL] [Abstract][Full Text] [Related]
13. RIPK1 promotes death receptor-independent caspase-8-mediated apoptosis under unresolved ER stress conditions.
Estornes Y; Aguileta MA; Dubuisson C; De Keyser J; Goossens V; Kersse K; Samali A; Vandenabeele P; Bertrand MJ
Cell Death Dis; 2014 Dec; 5(12):e1555. PubMed ID: 25476903
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Zhuang C; Chen F
J Med Chem; 2020 Feb; 63(4):1490-1510. PubMed ID: 31622096
[TBL] [Abstract][Full Text] [Related]
15. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
16. Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease.
Chan HH; Koh RY; Lim CL; Leong CO
Curr Alzheimer Res; 2019; 16(10):907-918. PubMed ID: 31642777
[TBL] [Abstract][Full Text] [Related]
17. Genetic Regulation of RIPK1 and Necroptosis.
Xu D; Zou C; Yuan J
Annu Rev Genet; 2021 Nov; 55():235-263. PubMed ID: 34813352
[TBL] [Abstract][Full Text] [Related]
18. Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Weisel K; Berger S; Papp K; Maari C; Krueger JG; Scott N; Tompson D; Wang S; Simeoni M; Bertin J; Peter Tak P
Clin Pharmacol Ther; 2020 Oct; 108(4):808-816. PubMed ID: 32301501
[TBL] [Abstract][Full Text] [Related]
19. Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Newton K
Cold Spring Harb Perspect Biol; 2020 Mar; 12(3):. PubMed ID: 31427374
[TBL] [Abstract][Full Text] [Related]
20. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.
Shutinoski B; Alturki NA; Rijal D; Bertin J; Gough PJ; Schlossmacher MG; Sad S
Cell Death Differ; 2016 Oct; 23(10):1628-37. PubMed ID: 27258786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
